Nirmatrelvir combined with ritonavir for preventing and treating COVID‐19
S Reis, MI Metzendorf, R Kuehn… - Cochrane Database …, 2023 - cochranelibrary.com
Background Oral nirmatrelvir/ritonavir (Paxlovid) aims to avoid severe COVID‐19 in
asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and …
asymptomatic people or those with mild symptoms, thereby decreasing hospitalization and …
Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics
Abstract Nirmatrelvir/ritonavir (N/R) is one of the most effective antiviral drugs against SARS-
CoV-2. The preclinical development, pharmacodynamics and pharmacokinetics of N/R are …
CoV-2. The preclinical development, pharmacodynamics and pharmacokinetics of N/R are …
Nirmatrelvir treatment of SARS‐CoV‐2‐infected mice blunts antiviral adaptive immune responses
V Fumagalli, P Di Lucia, M Ravà, D Marotta… - EMBO molecular …, 2023 - embopress.org
Alongside vaccines, antiviral drugs are becoming an integral part of our response to the
SARS‐CoV‐2 pandemic. Nirmatrelvir—an orally available inhibitor of the 3‐chymotrypsin …
SARS‐CoV‐2 pandemic. Nirmatrelvir—an orally available inhibitor of the 3‐chymotrypsin …
[HTML][HTML] An explanation for SARS-CoV-2 rebound after Paxlovid treatment
In a fraction of SARS-CoV-2 infected individuals treated with the oral antiviral Paxlovid, the
virus rebounds following treatment. The mechanism driving rebound is not understood …
virus rebounds following treatment. The mechanism driving rebound is not understood …
[HTML][HTML] Viral and symptom rebound in untreated COVID-19 infection
Background: There are reports of viral RNA and symptom rebound in people with COVID-19
treated with nirmatrelvir/ritonavir. Since the natural course of viral and symptom trajectories …
treated with nirmatrelvir/ritonavir. Since the natural course of viral and symptom trajectories …
Real-world effectiveness of nirmatrelvir/ritonavir on coronavirus disease 2019–associated hospitalization prevention: a population-based cohort study in the province …
JL Kaboré, B Laffont, M Diop, MR Tardif… - Clinical Infectious …, 2023 - academic.oup.com
Background Nirmatrelvir/ritonavir has shown to reduce COVID-19 hospitalization and death
before Omicron, but updated real-world evidence studies are needed. This study aimed to …
before Omicron, but updated real-world evidence studies are needed. This study aimed to …
[HTML][HTML] Nirmatrelvir plus ritonavir in COVID-19: a profile of its use
HA Blair - Drugs & Therapy Perspectives, 2023 - Springer
Oral nirmatrelvir plus ritonavir (Paxlovid™) is an effective treatment option for coronavirus
disease 2019 (COVID-19), the illness caused by severe acute respiratory syndrome …
disease 2019 (COVID-19), the illness caused by severe acute respiratory syndrome …
[HTML][HTML] Benefits of near-universal vaccination and treatment access to manage COVID-19 burden in the United States
Background As we continue the fourth year of the COVID-19 epidemic, SARS-CoV-2
infections still cause high morbidity and mortality in the United States. During 2020–2022 …
infections still cause high morbidity and mortality in the United States. During 2020–2022 …
Your Outpatient has Coronavirus Disease 2019: What Are the Treatment Options in the Current Severe Acute Respiratory Syndrome Coronavirus 2 Variant Climate?
Mutations accumulated by novel Severe Acute Respiratory Syndrome Coronavirus 2
Omicron sublineages contribute to evasion of previously effective monoclonal antibodies for …
Omicron sublineages contribute to evasion of previously effective monoclonal antibodies for …
Innovative approaches to COVID-19 medical countermeasure development
GH Harris, AA Adalja - Journal of Antimicrobial Chemotherapy, 2023 - academic.oup.com
Background The COVID-19 pandemic, while unfortunately notable for immense strain and
death throughout the world, has also shown great promise in the development of medical …
death throughout the world, has also shown great promise in the development of medical …